Merrill reiterates OSI at buy

Merrill Lynch analyst Eric Ende reiterated OSI Pharmaceuticals, Inc. at a buy on news that Genentech's Lucentis received Food and Drug Administration approval to treat age-related macular degeneration (AMD). Lucentis is likely to cut into Macugen's market share, according to the analyst. Merrill reduced its Macugen estimates to $187 million from $197 million in 2006 and to $123 million from $174 million in 2007. The analyst's loss-per-share estimate declines to a loss of $0.04 from a loss of $0.02 in 2006. Shares of the Melville, N.Y.-based pharmaceutical company were down $1.45, or 4.42%, at $31.35 on volume of 1,603,519 shares versus the three-month running average of 1227,320 shares. (Nasdaq: OSIP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.